CN111956671A - Composite probiotics for treating helicobacter pylori infection - Google Patents
Composite probiotics for treating helicobacter pylori infection Download PDFInfo
- Publication number
- CN111956671A CN111956671A CN202010642905.4A CN202010642905A CN111956671A CN 111956671 A CN111956671 A CN 111956671A CN 202010642905 A CN202010642905 A CN 202010642905A CN 111956671 A CN111956671 A CN 111956671A
- Authority
- CN
- China
- Prior art keywords
- helicobacter pylori
- lactobacillus
- hours
- composite
- composite probiotic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a composite probiotic for treating helicobacter pylori infection, wherein the probiotic is four single strains of lactobacillus plantarum, lactobacillus acidophilus, lactobacillus casei and lactobacillus rhamnosus, a culture medium is fresh goat milk, apple juice and distilled water, the four single strains are specially fermented to generate efficient composite probiotic, the four probiotics play a role together, the living environment of the helicobacter pylori is firstly changed, helicobacter pylori in stomach is eliminated, and then the growth of the helicobacter pylori is inhibited. All main raw materials in the invention are beneficial microorganisms, and are different from other hormone products. The product of the invention does not contain antibiotics, and simultaneously, the generation and the repeated growth of the helicobacter pylori can be quickly prevented through antagonism, space occupation and the like. And the production cost is low, and the raw materials are easy to obtain.
Description
Technical Field
The invention belongs to the technical field of probiotics, and particularly relates to a composite probiotic for treating helicobacter pylori infection.
Background
Stomach diseases are of various types and have complex causes. Chronic gastritis, which refers to various chronic gastric mucosal lesions caused by different etiological factors, is a common disease and a frequently encountered disease, the incidence of the chronic gastritis is the first of various gastric diseases, and the incidence of the chronic gastritis also increases with the age of a human body. The pathogeny is mainly caused by helicobacter pylori infection, long-term damage caused by irritant substances, stimulation of medicines, external environment change, irregular living diet and other factors.
Helicobacter pylori (Hp), a gram-negative bacterium, has extremely strong viability, can parasitize on gastric mucosa and is hidden in the stomach fovea, so that the helicobacter pylori can avoid the influence of the gastric acid environment and is not easy to be discharged out of the body along with food.
However, it will produce toxin in the process of growth and reproduction, destroy gastric mucosa, cause chronic and superficial gastritis and other diseases, gradually develop into gastric ulcer and even gastric cancer!
The human carcinogens of class I were introduced by the International agency for research on cancer (IARC) as early as 1994, and the risk of carcinogenesis was confirmed.
The helicobacter pylori infection progresses to gastric cancer, and is also required to undergo four stages of chronic superficial gastritis, atrophic gastritis, intestinal metaplasia and atypical hyperplasia.
Therefore, gastric cancer can be prevented by blocking intestinal metaplasia and previous lesions in time and removing helicobacter pylori.
If the infection with H.pylori is confirmed, follow the prescription to take a large dose of antibiotic for one week, and after 1 month, do the follow-up again until the H.pylori is eliminated!
This is not the case, however, because of the extremely high viability of H.pylori and the very high probability of reinfection, which means that repeated consumption of antibiotics can eliminate it, but too much antibiotics can cause a decrease in immunity and rather make it more susceptible!
Currently, triple or quadruple antibiotic therapy is basically adopted, and a better clinical effect is achieved. However, the side effects of the antibiotics are gradually obvious in the application of a large amount of the antibiotics, and the drug resistance of the viruses is generated. Therefore, by 2017, the infection rate of helicobacter pylori in China does not decrease or increase reversely to reach 60 percent, the number of infected people reaches nearly 8 hundred million, antibiotic treatment has no specificity to bacteria, bacteria are killed well and bad, the natural ecology of intestines and stomach is destroyed, and side effects of stomach discomfort such as nausea, diarrhea, abdominal distension and the like are caused. If the antibiotic treatment does not completely eliminate bacteria, the surviving bacteria are likely to become resistant to the drug, which leads to the trouble that the antibiotic treatment is not effective in the future.
A research paper published in 2014 in the journal of american clinical nutrition indicates that: the probiotic bacteria are safe and effective for persons infected with helicobacter pylori. Researchers found that if these particular experimental mice were allowed to ingest H.pylori, the bacteria would readily grow and multiply in their stomachs. However, if sterilized mice are previously fed with a probiotic-supplemented diet for several days and then allowed to ingest H.pylori, the mice have a strong resistance to the bacteria.
Disclosure of Invention
Aiming at the defect of triple or quadruple antibiotic therapy, the invention develops a simple, low-cost and high-efficiency composite probiotic treatment method without drug resistance.
The invention aims to provide a natural, safe and low-cost composite probiotic for treating helicobacter pylori infection.
The composite probiotics for treating helicobacter pylori infection is prepared according to the following method:
according to the lactobacillus plantarum: lactobacillus acidophilus: lactobacillus casei: rhamnose bacillus: glucose: distilled water =2-4:4-8:4-7: 6-10: 5-8: 20-28, stirring and standing for 4 hours for activation;
preparing culture medium from apple juice 5-10%, fresh goat milk 5-8%, and distilled water, and steam autoclaving at 115 deg.C for 15 min;
cooling the culture medium to room temperature, and inoculating activated lactobacillus plantarum, lactobacillus acidophilus, lactobacillus casei and lactobacillus rhamnosus bacterial liquid, wherein the inoculation amount is 2-5%;
after inoculation, firstly fermenting for 15-20 hours at the temperature of 32 ℃ and the rotating speed of 150r/min, and then fermenting for 6-10 hours at the temperature of 26 ℃ and the rotating speed of 100 r/min;
standing for 3-5 hours, filtering, and filling to obtain the composite probiotics.
According to the technical scheme, the probiotics are four single strains of lactobacillus plantarum, lactobacillus acidophilus, lactobacillus casei and lactobacillus rhamnosus, the culture medium is fresh goat milk, apple juice and distilled water, efficient composite probiotics are generated through special fermentation, the four probiotics play a role together, the survival environment of helicobacter pylori is changed, helicobacter pylori in the stomach is eliminated, and then the growth of the helicobacter pylori is inhibited.
Because the delicious food needs to be digested, the stomach belongs to a strong acid environment, many harmful and beneficial bacteria cannot survive in the stomach, and only the composite probiotics formed by lactobacillus plantarum, lactobacillus acidophilus, lactobacillus casei and lactobacillus rhamnosus can exist, so that the general probiotics can be killed by gastric acid to lose the activity, and needless to say, the probiotics are absorbed by the human body to play a role, and the dead probiotics are not useful!
All main raw materials in the invention are beneficial microorganisms, and are different from other hormone products. The key point of the technology is the proportion of lactobacillus plantarum to lactobacillus acidophilus, lactobacillus casei and lactobacillus rhamnosus and the composition of a culture medium.
The invention relates to a high-efficiency compound microbial liquid which is prepared by a special process of single strains such as lactobacillus plantarum and lactobacillus acidophilus. The beneficial total bacteria content per milliliter is more than or equal to 200 hundred million CFU.
The product of the invention does not contain antibiotics, and simultaneously, the generation and the repeated growth of the helicobacter pylori can be quickly prevented through antagonism, space occupation and the like. And the production cost is low, and the raw materials are easy to obtain.
The product of the invention destroys the protective layer of 'ammonia cloud' produced by the helicobacter pylori of the stomach, so that the product can not resist the bactericidal action of gastric juice. And competes with the gastric helicobacter pylori for the survival attachment space on the epithelial surface of the gastric mucosa, so that the gastric helicobacter pylori loses the survival advantage, the inflammation reaction is inhibited, and the repair of the gastric mucosa is facilitated.
(1) The protective layer is destroyed, and the probiotics excrete some active substances for resisting bacterial adhesion or certain antibacterial substances to prevent the helicobacter pylori from adhering to the gastric epithelial cells.
(2) Repairing damaged gastric mucosa, balancing the proportion of gastric acid strains, rapidly absorbing harmful inflammatory substances generated by helicobacter pylori, and balancing gastric acid secretion.
(3) Improving gastric immunity, and reconstructing immune barrier. Can remarkably improve the functions of a gastric immune system and a gastric lymph immune system, rebuild a microecological immune barrier, form a new intragastric microecological balance system, improve the immunity of a human body to helicobacter pylori and prevent the helicobacter pylori from rebounding.
(4) Regulating intestinal flora and reducing adverse reverberation: the product of the invention can regulate the intestinal flora imbalance, maintain the intestinal microecological balance and prevent the adverse effects (diarrhea/constipation, etc.) caused by antibiotics.
Detailed Description
The composite probiotics for treating helicobacter pylori infection is prepared according to the following method:
according to the lactobacillus plantarum: lactobacillus acidophilus: lactobacillus casei: rhamnose bacillus: glucose: distilled water =2-4:4-8:4-7: 6-10: 5-8: 20-28, stirring and standing for 4 hours for activation;
preparing culture medium from apple juice 5-10%, fresh goat milk 5-8%, and distilled water, and steam autoclaving at 115 deg.C for 15 min;
cooling the culture medium to room temperature, and inoculating activated lactobacillus plantarum, lactobacillus acidophilus, lactobacillus casei and lactobacillus rhamnosus bacterial liquid, wherein the inoculation amount is 2-5%;
after inoculation, firstly fermenting for 15-20 hours at the temperature of 32 ℃ and the rotating speed of 150r/min, and then fermenting for 6-10 hours at the temperature of 26 ℃ and the rotating speed of 100 r/min;
standing for 3-5 hours, filtering, and filling to obtain the composite probiotics.
The usage and dosage are as follows: orally taking 30 ml once and three times a day. One month is a course of treatment, the taking of the medicine is not less than two courses of treatment, and the taking of the medicine is forbidden: antibiotics are prohibited.
Clinical observation data of the composite probiotics of the invention
1. General data clinical data:
the treatment method is that on the premise of voluntary treatment of patients or family members, the patients are randomly divided into two groups, 100 patients are treated by using the composite probiotics of the invention;
control group 100, quadrupletherapy (omeprazole 20 mg taken 30 minutes before meal, bismuth potassium citrate 220 mg taken 30 minutes before meal, clarithromycin 500 mg taken immediately after meal, amoxicillin one thousand mg taken immediately after meal).
The curative effect standard is as follows:
and (3) curing: the symptoms disappeared, with a test value < 100.
Improvement: the symptoms are reduced. The detection value is >100.
The disease is not cured: the symptoms and signs are unchanged, and the detection value is more than 100.
3. Analysis of results
Comparison of therapeutic effects (see Table below)
| Group of | Number of examples | Cure of disease | Show effect | Improvement of life | Invalidation | Cure rate | Total effective rate |
| Treatment group | 100 | 89 | 5 | 6 | 0 | 89% | 100% |
| Control group | 100 | 68 | 20 | 5 | 7 | 68% | 93% |
The curative effect of the treatment group is obviously better than that of the control group, and the cure rate and the total effective rate (89 percent and 100 percent) are obviously higher than those of the control group (68 percent and 93 percent).
4. Typical cases are as follows: carbon 14 breath test reports a 30 minute DOB value
Claims (2)
1. A composite probiotic for treating helicobacter pylori infection, characterized in that the composite probiotic is prepared according to the following method:
according to the lactobacillus plantarum: lactobacillus acidophilus: lactobacillus casei: rhamnose bacillus: glucose: distilled water =2-4:4-8:4-7: 6-10: 5-8: 20-28, stirring and standing for 4 hours for activation;
preparing culture medium from apple juice 5-10%, fresh goat milk 5-8%, and distilled water, and steam autoclaving at 115 deg.C for 15 min;
cooling the culture medium to room temperature, and inoculating activated lactobacillus plantarum, lactobacillus acidophilus, lactobacillus casei and lactobacillus rhamnosus bacterial liquid, wherein the inoculation amount is 2-5%;
after inoculation, firstly fermenting for 15-20 hours at the temperature of 32 ℃ and the rotating speed of 150r/min, and then fermenting for 6-10 hours at the temperature of 26 ℃ and the rotating speed of 100 r/min;
standing for 3-5 hours, filtering, and filling to obtain the composite probiotics.
2. The composite probiotic bacteria for treating helicobacter pylori infection according to claim 1, wherein said composite probiotic bacteria contain more than or equal to 200 hundred million CFU (total number of beneficial bacteria) per ml.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010642905.4A CN111956671A (en) | 2020-07-06 | 2020-07-06 | Composite probiotics for treating helicobacter pylori infection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010642905.4A CN111956671A (en) | 2020-07-06 | 2020-07-06 | Composite probiotics for treating helicobacter pylori infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111956671A true CN111956671A (en) | 2020-11-20 |
Family
ID=73361114
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010642905.4A Pending CN111956671A (en) | 2020-07-06 | 2020-07-06 | Composite probiotics for treating helicobacter pylori infection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111956671A (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112353823A (en) * | 2020-12-16 | 2021-02-12 | 梁爱军 | Probiotic liquid capable of playing roles in stomach and intestine simultaneously |
| CN112438998A (en) * | 2020-11-27 | 2021-03-05 | 四川大学 | Probiotics agent PAPH for preventing and treating helicobacter pylori infection and preparation method thereof |
| CN112458020A (en) * | 2020-12-04 | 2021-03-09 | 嘉兴益诺康生物科技有限公司 | Probiotic composition for inhibiting helicobacter pylori and application thereof |
| CN112641799A (en) * | 2021-02-08 | 2021-04-13 | 孙欧希 | Application of oxygen-enriched water in elimination of helicobacter pylori in stomach |
| CN112914103A (en) * | 2021-02-22 | 2021-06-08 | 漯河微康生物科技有限公司 | Probiotic composition for resisting helicobacter pylori infection and application thereof |
| CN112940984A (en) * | 2021-03-31 | 2021-06-11 | 盐城维康生物科技有限公司 | Compound lactobacillus preparation for resisting helicobacter pylori, reducing blood sugar, conditioning intestines and stomach and increasing immunity and preparation method thereof |
| CN113384662A (en) * | 2021-07-13 | 2021-09-14 | 镇江市天益生物科技有限公司 | Helicobacter pylori-resistant probiotic composition and preparation method and application thereof |
| CN113662192A (en) * | 2021-08-02 | 2021-11-19 | 石家庄君乐宝乳业有限公司 | Anti-helicobacter pylori instant lactic acid bacteria agent and preparation method and application thereof |
| WO2024121103A1 (en) * | 2022-12-05 | 2024-06-13 | International N&H Denmark Aps | Probiotics for treating and/or preventing conditions associated with helicobacter pylory colonization |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102784172A (en) * | 2012-08-16 | 2012-11-21 | 薛松晓 | Compound probiotics for treating irritable bowel syndrome and preparation method thereof |
| CN105995972A (en) * | 2016-05-13 | 2016-10-12 | 晶叶（青岛）生物科技有限公司 | Symbiotic microflora enzyme, application thereof and food prepared from symbiotic microflora enzyme |
| CN108904546A (en) * | 2018-07-10 | 2018-11-30 | 山东腾贵医药有限公司 | A kind of pair of helicobacter pylori has inhibition, the probiotic combinations preparation of killing effect and preparation method thereof |
| CN109464487A (en) * | 2018-11-28 | 2019-03-15 | 吉林禾未来功能产品有限公司 | Probiotics compound of anti-helicobacter pylori and preparation method thereof |
| US20200077692A1 (en) * | 2018-09-12 | 2020-03-12 | Genmont Biotech Incorporation | Lactobacillus composition for inhibiting gastritis induced by gastric helicobacter pylori and use thereof |
| CN113546148A (en) * | 2021-09-07 | 2021-10-26 | 薛松晓 | Compound probiotic preparation for treating femoral head necrosis and preparation method thereof |
-
2020
- 2020-07-06 CN CN202010642905.4A patent/CN111956671A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102784172A (en) * | 2012-08-16 | 2012-11-21 | 薛松晓 | Compound probiotics for treating irritable bowel syndrome and preparation method thereof |
| CN105995972A (en) * | 2016-05-13 | 2016-10-12 | 晶叶（青岛）生物科技有限公司 | Symbiotic microflora enzyme, application thereof and food prepared from symbiotic microflora enzyme |
| CN108904546A (en) * | 2018-07-10 | 2018-11-30 | 山东腾贵医药有限公司 | A kind of pair of helicobacter pylori has inhibition, the probiotic combinations preparation of killing effect and preparation method thereof |
| US20200077692A1 (en) * | 2018-09-12 | 2020-03-12 | Genmont Biotech Incorporation | Lactobacillus composition for inhibiting gastritis induced by gastric helicobacter pylori and use thereof |
| CN109464487A (en) * | 2018-11-28 | 2019-03-15 | 吉林禾未来功能产品有限公司 | Probiotics compound of anti-helicobacter pylori and preparation method thereof |
| CN113546148A (en) * | 2021-09-07 | 2021-10-26 | 薛松晓 | Compound probiotic preparation for treating femoral head necrosis and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 袁凯涛;刘冠环;左继东;: "唾液乳杆菌、嗜酸乳杆菌及植物乳杆菌三联活菌制剂联合三联疗法根除幽门螺杆菌的临床研究", 中国医学创新, no. 10 * |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112438998A (en) * | 2020-11-27 | 2021-03-05 | 四川大学 | Probiotics agent PAPH for preventing and treating helicobacter pylori infection and preparation method thereof |
| CN112438998B (en) * | 2020-11-27 | 2023-01-10 | 四川大学 | Probiotics agent PAPH for preventing and treating helicobacter pylori infection and preparation method thereof |
| CN112458020A (en) * | 2020-12-04 | 2021-03-09 | 嘉兴益诺康生物科技有限公司 | Probiotic composition for inhibiting helicobacter pylori and application thereof |
| CN112458020B (en) * | 2020-12-04 | 2022-02-18 | 嘉兴益诺康生物科技有限公司 | Probiotic composition for inhibiting helicobacter pylori and application thereof |
| CN112353823A (en) * | 2020-12-16 | 2021-02-12 | 梁爱军 | Probiotic liquid capable of playing roles in stomach and intestine simultaneously |
| CN112641799A (en) * | 2021-02-08 | 2021-04-13 | 孙欧希 | Application of oxygen-enriched water in elimination of helicobacter pylori in stomach |
| CN112914103A (en) * | 2021-02-22 | 2021-06-08 | 漯河微康生物科技有限公司 | Probiotic composition for resisting helicobacter pylori infection and application thereof |
| CN112940984A (en) * | 2021-03-31 | 2021-06-11 | 盐城维康生物科技有限公司 | Compound lactobacillus preparation for resisting helicobacter pylori, reducing blood sugar, conditioning intestines and stomach and increasing immunity and preparation method thereof |
| CN113384662A (en) * | 2021-07-13 | 2021-09-14 | 镇江市天益生物科技有限公司 | Helicobacter pylori-resistant probiotic composition and preparation method and application thereof |
| CN113662192A (en) * | 2021-08-02 | 2021-11-19 | 石家庄君乐宝乳业有限公司 | Anti-helicobacter pylori instant lactic acid bacteria agent and preparation method and application thereof |
| CN113662192B (en) * | 2021-08-02 | 2024-07-02 | 君乐宝乳业集团有限公司 | Instant lactobacillus agent for resisting helicobacter pylori, preparation method and application thereof |
| WO2024121103A1 (en) * | 2022-12-05 | 2024-06-13 | International N&H Denmark Aps | Probiotics for treating and/or preventing conditions associated with helicobacter pylory colonization |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111956671A (en) | Composite probiotics for treating helicobacter pylori infection | |
| CN110101722B (en) | Application of composite probiotic preparation in preparation of product for treating ulcerative colitis | |
| CN112386615B (en) | Application of lactobacillus paracasei JLPF-176 for inhibiting helicobacter pylori infection and product | |
| CN112914103A (en) | Probiotic composition for resisting helicobacter pylori infection and application thereof | |
| CN111011856A (en) | Composition for relieving gastropathy, preparation method thereof and food for relieving gastropathy | |
| CN111602810A (en) | Probiotic clausena lansium microcapsule and preparation method and application thereof | |
| CN113832077A (en) | Lactobacillus rhamnosus and application thereof | |
| CN115607577B (en) | Probiotics with efficacy of relieving stomatitis, and preparation method and application thereof | |
| CN110623984A (en) | Quadruple viable bacteria preparation for treating diarrhea and application thereof | |
| CN112471353A (en) | Long-acting symbiotic composite liquid microecological preparation for poultry feeding and preparation method thereof | |
| CN111254088A (en) | Bacillus coagulans strain and application thereof | |
| CN114908020A (en) | Lactobacillus plantarum for resisting helicobacter pylori infection and application of lactobacillus plantarum in edible herbal enzyme product | |
| CN115120646A (en) | Probiotic composition for balancing intestinal flora and preparation method and application thereof | |
| CN113969253B (en) | Bifidobacterium lactis JYBR-390 with constipation treatment effect and application and product thereof | |
| CN115119940A (en) | Application of Lactobacillus acidophilus LA85 and Bifidobacterium lactis BLA80 in inhibiting helicobacter pylori | |
| CN117327632B (en) | Bifidobacterium animalis and application thereof | |
| CN112940984B (en) | Compound lactobacillus preparation for resisting helicobacter pylori, reducing blood sugar, regulating intestines and stomach and increasing immunity and preparation method thereof | |
| CN114287633A (en) | Probiotic composition containing cranberry and application of probiotic composition in resisting helicobacter pylori | |
| CN110960562A (en) | Probiotic composition with anti-allergy effect | |
| CN111544456A (en) | Probiotic formula and application thereof | |
| CN114836349B (en) | Lactobacillus acidophilus LA16 for antagonizing helicobacter pylori and application thereof | |
| CN112980736A (en) | Lactobacillus casei preparation capable of improving gastrointestinal function conditioning effect and preparation method thereof | |
| CN113151037A (en) | Preparation method of rabdosia amethystoides fermentation preparation and application of rabdosia amethystoides fermentation preparation in antitumor treatment | |
| CN110628683A (en) | Probiotic compound live bacterium preparation for preventing and treating chicken diarrhea and preparation method thereof | |
| CN116731913B (en) | Application of lactobacillus plantarum in preparation of helicobacter pylori resistant products |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |